{"url_path":"/sec/aemd/8-k/2026-06-04/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **** Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/882291/0001683168-26-004540-index.html","accession_number":"0001683168-26-004540","cik":"0000882291","ticker":"AEMD","issuer_name":"AETHLON MEDICAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/882291/0001683168-26-004540-index.html","primary_entity_key":"0000882291","primary_entity_name":"AETHLON MEDICAL INC"},"word_count":439,"has_tables":true,"body_markdown":"**Item 8.01.**** Other Events.**\n\n** **\n\nOn December 23, 2025, Aethlon Medical, Inc., a\nNevada corporation (the “Company”), filed a prospectus supplement (the “Prospectus Supplement”) with the\nSecurities and Exchange Commission (the “Commission”) relating to the offer and sale of shares of the Company's common\nstock, par value $0.001 per share (“Common Stock”), from time to time pursuant to that certain At Market Offering\nAgreement, dated March 24, 2022, as amended on December 19, 2025 (the “ATM Agreement”), by and between the Company and\nH.C. Wainwright & Co., LLC (“Wainwright”). The Prospectus Supplement was filed together with the base prospectus\ndated January 2, 2026 (the “Base Prospectus” and together with the Prospectus Supplement, the “Prospectus”),\nunder the Company's Registration Statement on Form S-3 (File No. 333-292405), which became effective on January 2, 2026 (the\n“Registration Statement”).\n\n \n\nOn June 4, 2026, the Company filed Amendment No.\n1 to the Prospectus Supplement (the “Amendment” and together with the Base Prospectus and the Prospectus Supplement, the “Prospectus”),\namending and supplementing the Prospectus Supplement to update the amount of shares eligible for sale pursuant to General Instruction\nI.B.6 of Form S-3. Following the filing of the Amendment, the Company may offer and sell shares of Common Stock having an aggregate offering\nprice of up to $542,716 pursuant to the ATM Agreement (the “Placement Shares”). This amount is in addition to the shares of\nCommon Stock having an aggregate sales price of $1,849,457 that were previously sold pursuant to the Prospectus Supplement prior to the\nfiling of the Amendment. As of June 1, 2026, the Company had 2,344,886 shares of Common Stock outstanding, of which 2,337,629 shares were\nheld by non-affiliates for purposes of calculating the Company's public float under General Instruction I.B.6 of Form S-3. All other terms\nof the offering and the ATM Agreement remain unchanged and are described in the Prospectus Supplement and the ATM Agreement.\n\n \n\nThe legal opinion of Procopio, Cory, Hargreaves\n& Savitch, LLP relating to the Placement Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K.\n\n \n\nThe offering of the Placement Shares has been\nregistered pursuant to the Registration Statement, and any offering of the Placement Shares will be made only by means of the Prospectus.\nThis Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any of the Placement Shares\ndescribed herein, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation\nor sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction."}